There was some evidence to suggest that patients with NRAS mutant tumours compared to those with BRAF/NRAS wild-type tumours had an increased risk of developing disease recurrence following a negative SLNB (aHR = 1.72, 95% CI 0.80–3.67, p = 0.16). This evidence concerns the gene BRAF and neoplasm.